Company: PFSA
Filing Date: 2025-10-29
Form Type: 424B3
Source: 0001213900-25-103174
Chunk: 266

Company: Profusa, Inc.
Filing Date: 2025-10-29
Form: 424B3
Chunk 266
---
 |              |        |   |     |      |         |   |
| Increase in unpaid deferred offering costs                                  |     | $            |    269 |   |     | $    |      72 |   |

<div align='center'>The accompanying notes are an integral part of
these consolidated financial statements.

F-6

PROFUSA, INC. AND SUBSIDIARY
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</div>

Note 1 — Organization, Description of Business, Going Concern and Significant Risks and Uncertainties

Description of Business

Profusa, Inc. (the “Company”)
was incorporated in the state of California on May 11, 2009. The Company engaged in the development of a new generation of biointegrated
sensors that potentially empowers the individual with the ability to monitor their unique body chemistry.

The Company’s technology
enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable,
clinical-grade data for personal and medical use. The Company’s first offering in the European Union, the Lumee™ Oxygen Platform,
is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term. The Lumee™ Oxygen
Platform has been designed for use in applications where monitoring of compromised tissue is beneficial, such as peripheral artery disease
that results in narrowing of blood vessels and reduced blood flow to the lower limbs; chronic wounds (diabetic ulcers, pressure sores)
that do not heal properly; and reconstructive surgery.

The Company’s research
and development efforts are primarily focused on its Lumee™ Glucose Platform which is a system designed to monitor glucose levels
in interstitial fluid, continuously and long-term. A tiny, biocompatible gel injected under the skin acts as a continuous glucose monitor
(CGM) for several months. The ability of Lumee™ Glucose to provide continuous glucose monitoring with only an initial
single injection, is an attractive alternative for people with diabetes to manage their disease without the need for frequent finger sticks
required by standard glucometers, or the need for weekly sensor replacement as required by current short-term needle-type CGMs.

On November 6, 2022, the
Company’s board of directors unanimously approved the pursuit of a business combination transaction involving the Company. On November 7,
2022, the Company entered into an Agreement and Plan of Merger (“Merger”) with NorthView Acquisition Corp